A phase III study of combination therapy with everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor (JCOG1901, STARTER-NET) ...

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced three abstracts from its clinical development programs will be presented at the upcoming ...

Carcinoid and Neuroendocrine Tumors: Building on Success The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated.

In clinical practice, dose adjustment for SSAs is a common strategy used to manage patients with neuroendocrine tumors (NETs). The primary reason for escalating the dose is to achieve better symptom ...

Effective coordination among multidisciplinary team and individualized management strategies has emerged as a cornerstone of optimal NET care.

Dr. Elliott Winford (Medicine): An 86-year-old man was admitted to this hospital because of shortness of breath. The patient had been in his usual state of health until 6 months before the current ...